IGFBP1 and osteosarcoma: The patients with metastatic (50.46 ± 3.29) and recurrent (52.11 ± 3.29) osteosarcoma tumors produced a significantly higher level of IGFBP-1 compared to patients with non-metastatic (40.80 ± 2.66) (P=0.04) and non-recurrent (40.64 ± 2.53) (P=0.009) osteosarcoma tumors (Figure 5D).